Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its fourth quarter revenues rose 88 percent year over year, thanks largely to a 120 percent increase in testing services revenues.

For the three months ended Dec. 31, 2018 the transplant diagnostics company reported total revenues of $23.5 million, up from $12.5 million a year earlier, and beat the average Wall Street analyst estimate of $23.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.